Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Artivion, Inc. (AORT) Guidance & Earnings Results

On 2026-08-06 Artivion, Inc. reaffirmed guidance: "Revenue $480-496M, adjusted EBITDA…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

AORTArtivion, Inc.Follow AORT — free
Medical Devices · Healthcare
—
Price chart with a free account
Market cap
1.1B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
10 Feb, in 109 days

What management guided

each earnings 8-K · figures checked against the filing text
ReleaseDirectionWhat they said
6 Aug 26ReaffirmedRevenue $480-496M, adjusted EBITDA $92-99M · full year
12 Feb 26Reaffirmeddouble-digit constant currency revenue growth; adjusted EBITDA growth at twice the pace · full year
6 Nov 25RaisedFY2025 constant currency revenue growth raised to 13-14% from 12-14%; adjusted EBITDA growth raised to 24-28% from 21-28% · full year
7 Aug 25RaisedFY2025 constant currency revenue growth raised to 12-14% from 11-14%; reported revenue guidance raised to $435-443M from $423-435M; FY2025 adjusted EBITDA growth raised to 21-28% from 18-28%; adjusted EBITDA guidance raised to $86-91M from $84-91M · full year

Artivion, Inc. — questions

What guidance did Artivion, Inc. give?
On 2026-08-06: "Revenue $480-496M, adjusted EBITDA $92-99M"
When does Artivion, Inc. report earnings?
Artivion, Inc.'s next earnings report is expected on 2027-02-10.

Every figure on this page comes from Artivion, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.